Experimental RSV vaccine shows promise

There is some new hope for parents and hospitals overwhelmed by children sick with RSV. An experimental vaccine is showing promise.

Pfizer says new data for its experimental shot was 69% effective in preventing severe respiratory illness in newborns their first six months of life.

The shot is given to pregnant women early in the third trimester.

The company says it’s even more effective in the first three months of life.

Pfizer’s data has not yet been peer reviewed.

The company says it plans to apply for approval of the vaccine before the end of the year, but shots in arms may not come until next winter.